Floatz logo

Ranolazine

Type 2 Diabetes Mellitus

Gilead SciencesSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

142 Active assets in the Type 2 Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Liraglutide
RenJi Hospital
Phase 4BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Ranolazine is also rated in:

myocardial ischemiaDormant
A
Indicative ·
82 / 100
View asset →
coronary artery disorderDormant
BBB
Indicative ·
75 / 100
View asset →
myocardial ischemiaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →